Kurma welcomes Amanda Gett-Chaperot as a Partner based in Paris. Amanda brings venture, industry and research experience, well aligned with our Biofund investment strategy.

Kurma’s Biofunds constitute our therapeutic venture franchise, investing at pre-seed stage to growth capital, with a significant emphasis on company creation in Europe. The Biofund franchise is building in strength and as we further our momentum, we are delighted to welcome a new member to the team.

Amanda has been investor and board member of biotech companies from sourcing to exit, as Partner at Seventure Partners and prior, Investment Manager at the Roche Venture Fund. Earlier at Roche, in roles as Global Business Development Director and Strategy Director Emerging Technologies, she focussed on external innovation through in-licensing and collaborations with biotechs and academia. Amanda began her career in academic research (ISREC, Lausanne and IRB, Bellinzona), holding a PhD in Immunology and BMedSci with First Class Honours from the University of Sydney and an MBA from IE Business School. 


About Kurma Partners 
Founded in 2009 in Paris, Kurma Partners has become a key player in Europe, financing innovation to build the healthcare industry of tomorrow. Kurma invests from company formation to growth capital, across the spectrum of healthcare through specialised franchises. The franchises continue to expand with successive funds focused on biotechnology (Biofunds I, II and III), digital health & diagnostics (Kurma Diagnostics and Kurma Diagnostics 2) and more recently, growth opportunities (Kurma Growth Opportunity Fund). Kurma’s teams based in Paris and Munich, are embedded within the European ecosystem and have strong international networks spanning prestigious research institutes and hospitals, entrepreneurs, industry and investors. www.kurmapartners.com